UNSPSC 51171723: Lidamidine hydrochloride

This classification denotes an antidiarrheal agent with the molecular formula C11H16N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q1Q4QJV3V, chemically known as 1-(methylamidino)-3-(2,6-xylyl)urea monohydrochloride but more generally known as lidamidine hydrochloride, which bears US NIH Compound Identifier 47509. European Medicines Agency schedules Lidamidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35843.

Most nations, for tariff and trade purposes, schedule lidamidine hydrochloride under HS 29252900 and SITC 51482. As of Q4 2014, LIDAMIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lidamidine hydrochloride bears US NLM identifiers UMLS ID C0771745 and NCI Concept Code C82241. SMILES: CC1CCCC(C1NC(=O)NC(=N)NC)C.CL.

UNSPSC 51171723 Lidamidine hydrochloride is a Commodity code that in practice covers drug-testing reagents and related laboratory services procured by state and local criminal justice and community supervision agencies. Recent state and local activity under this code reflects procurement of complete offender drug-testing programs — including specimen collection logistics, immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), and alternative testing methodologies such as oral fluid and hair analysis — rather than the chemical itself in isolation. Issuing bodies are primarily county corrections and community supervision departments operating under state criminal justice appropriations.

Collin County, Texas is the principal recent buyer, having posted RFP 2026-327 in September 2026 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 at 2:00 p.m. and an estimated contract value of $600,000. The county seeks vendors to operate two collection sites in Plano and McKinney (Monday–Friday 8:00 a.m. to 5:00 p.m., plus five Saturday half-days annually), manage an Interactive Voice Response randomized testing notification system, perform approximately 25,031 annual tests comprising five-panel and six-panel immunoassay screens with confirmatory analysis, and maintain SAMHSA, TX DPS, or CAP lab certification. The contract term runs two years from September 1, 2026, with three optional one-year renewal periods. Vendors must submit per-test pricing for three service models (screening only, confirmation after screening, and screening with automatic confirmation), with all-inclusive pricing and price redetermination capped at 3.0 percent annual medical Consumer Price Index increases. Award will go to the responsible contractor offering the best evaluated combination of vendor understanding and qualifications (55 points combined), client references (15 points), cost (30 points), and optional demonstrations or interviews (up to 30 additional points).